Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 11;14(3):578.
doi: 10.3390/v14030578.

VCAM-1 as a Biomarker of Endothelial Function among HIV-Infected Patients Receiving and Not Receiving Antiretroviral Therapy

Agnieszka Lembas  1 , Katarzyna Zawartko  2 , Mariusz Sapuła  1 , Tomasz Mikuła  1 , Joanna Kozłowska  1 , Alicja Wiercińska-Drapało  1
Affiliations

VCAM-1 as a Biomarker of Endothelial Function among HIV-Infected Patients Receiving and Not Receiving Antiretroviral Therapy

Agnieszka Lembas et al. Viruses. .

Abstract

The Human Immunodeficiency Virus and retroviral therapy are both known risk factors for cardiovascular disease. It remains an open question whether HIV or ARV leads to increased arterial inflammation. The objective of this study was to investigate the changes in endothelial activation by measuring VCAM-1 levels among HIV-infected patients who were and were not treated with antiretroviral therapy. It is a retrospective study that included 68 HIV-infected patients, 23 of whom were never antiretroviral-treated, 15 who were ART-treated for no longer than a year, and 30 who were ART-treated for longer than a year. Blood samples were collected for biochemical analysis of the concentration of VCAM-1. The results show a statistically lower VCAM-1 level (p = 0.007) in patients treated with ART longer than a year (1442 ng/mL) in comparison to treatment-naïve patients (2392 ng/mL). The average VCAM-1 level in patients treated no longer than a year (1552 ng/mL) was also lower than in treatment-naïve patients, but with no statistical significance (p = 0.096). Long-term antiretroviral therapy was associated with the decline of VCAM-1 concentration. That may suggest the lowering of endothelial activation and the decreased risk of the development of cardiovascular disease among ARV-treated patients. However, VCAM-1 may not be a sufficient factor itself to assess this, since simultaneously there are a lot of well-known cardiovascular-adverse effects of ART.

Keywords: HIV; VCAM-1; cardiovascular; endothelium; marker.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Distribution of VCAM-1 concentrations in healthy volunteers and examined groups of patients.
See this image and copyright information in PMC

References

    1. UNAIDS Fact Sheet—Latest Statistics on the Status of the AIDS Epidemic. 2019. [(accessed on 31 January 2020)]. Available online: https://www.unaids.org/en/resources/fact-sheet.
    1. National AIDS Centre Basic Epidemiologic Information. [(accessed on 31 January 2020)];2019 Available online: https://aids.gov.pl/hiv_aids/450-2-2/
    1. Rosenson R.S., Hubbard D., Monda K.L., Reading S.R., Chen L., Dluzniewski P.J., Burkholder G.A., Muntner P., Colantonio L.D. Excess Risk for Atherosclerotic Cardiovascular Outcomes among US Adults with HIV in the Current Era. J. Am. Hear. Assoc. 2020;9:e013744. doi: 10.1161/JAHA.119.013744. - DOI - PMC - PubMed
    1. Kralj V., Bilos I.B. Morbidity and mortality from cardiovascular diseases. Cardiol. Croat. 2013;8:373–378. doi: 10.15836/ccar.2013.373. - DOI
    1. Feinstein M.J., Bahiru E., Achenbach C., Longenecker C.T., Hsue P., So-Armah K., Freiberg M.S., Lloyd-Jones D. Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013. Am. J. Cardiol. 2016;117:214–220. doi: 10.1016/j.amjcard.2015.10.030. - DOI - PMC - PubMed